Evaluation of a simplified optimizer for MR-guided adaptive RT in case of pancreatic cancer.
CONCLUSION: Simplified optimization solutions implemented in the MR-Linac TPS allows to elaborate in most of cases treatment plans dosimetrically comparable with those obtained by using an advanced optimizer. A superior treatment plan quality is possible using the VMAT technique that could represent a breakthrough for the MRgART if the modern advancements will lead to shorter optimization times. PMID: 31444952 [PubMed - as supplied by publisher]
Abstract PURPOSE: Stereotactic body radiation therapy is a promising treatment modality for locally advanced pancreatic cancer. To determine the optimal radiation treatment, we compared the plan characteristics of volumetric-modulated arc therapy and intensity-modulated radiation therapy when administered with stereotactic body radiation therapy to treat pancreatic cancer. PATIENTS AND METHODS: Fifteen patients with locally advanced pancreatic cancer were treated by stereotactic body radiation therapy at a dose of 24-32Gy in four fractions with marker-guided gated volumetric-modulated arc therapy. Four dimens...
Conclusion.R0 resection, the goal of neoadjuvant treatment, can be achieved in 70% of patients presenting with locally advanced pancreatic cancer. The median DFS was 31 months (95% CI: 11. 3–51.1). No relationship was found with tumor size, degree of vascular involvement, carcinoembryonic antigen test (CEA), CA 19‐9, degree of tumor regression on scan, fall in CA 19‐9, or SUV on PET scan and subsequent survival.
CONCLUSION: R0 resection, the goal of neoadjuvant treatment, can be achieved in 70% of patients presenting with locally advanced pancreatic cancer. The median DFS was 31 months (95% CI: 11. 3-51.1). No relationship was found with tumor size, degree of vascular involvement, carcinoembryonic antigen test (CEA), CA 19-9, degree of tumor regression on scan, fall in CA 19-9, or SUV on PET scan and subsequent survival. PMID: 29212734 [PubMed - as supplied by publisher]
Conclusions In our series, approximately 11% of patients with pancreatic cancer have asymmetrical kidney function not identified by kidney size, serum BUN, Cr, GFR, or a significant past medical history. These data suggest that in cases where renal radiation doses exceed a V18 of 20–30%, or there is concern about baseline renal function, a functional renal scan should be considered.
CONCLUSIONS: Our ultrasound system can be potentially used for real-time monitoring during pancreas SBRT without compromising planning quality. The phantom study showed high monitoring accuracy of the system, and the volunteer study showed feasibility of the clinical workflow. PMID: 28574192 [PubMed - as supplied by publisher]
Pancreatic cancer has been one of the ten most common cancers worldwide for more than ten years . Compared to photon beam therapy, particle beam delivers a higher dose to the target lesion with greater sparing of organs at risk (OARs). Bouchard et al. investigated dose distribution dependency on tumour location using three-dimensional conformal photon-radiation therapy (3DCRT), intensity-modulated radiation therapy (IMRT), and passive-scattering proton therapy in pancreatic tumour treatment .
A 68-year-old woman suspected of having pancreatic body/tail cancer underwent EUS-guided FNA for pathologic confirmation. EUS-guided FNA with 2 passes using a 22G needle was conducted through the body of the stomach, and the diagnosis of pancreatic cancer was confirmed. The patient was treated using intensity-modulated radiation therapy and remained stable for 4 months. At that time, positron emission spectroscopy (PET)/CT showed indeterminate weak accumulation at the gastric wall with a maximum stand ardized uptake value of less than 3.5 (A).
In conclusion, target matching is required to correct interfraction variation even with visual feedback, especially to ensure safe delivery of escalated doses to patients with pancreatic cancer. PMID: 26103180 [PubMed - in process]
In conclusion, target matching is required to correct interfraction variation even with visual feedback, especially to ensure safe delivery of escalated doses to patients with pancreatic cancer.
Conclusion: there is no increased risk of doing the lymph node dissection early on. Dr. Eggener-CON Basics Lymph node dissections rarely done, even for large tumors, because there is no proven therapeutic or staging benefit for low risk patients. A Mayo study revealed no data showing therapeutic benefit in high risk patients. For clinically node negative high risk patients, there is staging value but no proven therapeutic benefit. Rate of positive nodes is associated with stage and grade; the higher the stage and grade, the more likely there will be positive nod...